INZY
Inozyme Pharma
INZY
INZY
Delisted
INZY was delisted on the 30th of June, 2025.
37 hedge funds and large institutions have $30.4M invested in Inozyme Pharma in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less ownership
Funds ownership: →
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
64% less capital invested
Capital invested by funds: $84.6M → $30.4M (-$54.2M)
Holders
37
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$529K | |
| 2 | +$525K | |
| 3 | +$473K | |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$292K |
| 5 |
CA
CHI Advisors
New York
|
+$219K |
Top Sellers
| 1 | -$5.6M | |
| 2 | -$3.81M | |
| 3 | -$1.63M | |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$452K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$444K |